Adipsin
CFDproteinAdipokine regulating systemic inflammation and metabolic risk in coronary disease progression.
Pathway placement
Cascade stepOff-pathway / systemic markers
Confidencemedium
RationaleAdipokine associated with metabolic/systemic MI risk, not plaque-specific.
Also acts inVascular inflammation
Druggability
Not assessed (no mapped human gene target).
Type I vs Type II discrimination
ScoresLow-confidence (proxy)
R — rupture / Type-I85
C — confounder / Type-II70
A — assay feasibility68
E — evidence strength33
T1DI (composite)13
Specificity differential (R−C)+15.1
Confounder panel (Type-II drivers)
No confounder evidence retrieved.
Tier: light (literature co-occurrence proxy — lower confidence). See the discrimination table for all markers.
Assay & specimen
Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum or plasma
Collection tube
Serum separator (gold/red-top, SST) · K2/K3-EDTA (lavender-top)
Method / principle
Sandwich immunoassay (ELISA) — research-grade unless a cleared assay exists
Reagent / substrate
Matched anti-target antibody pair (capture + labeled detection)
Platform
ELISA microplate or multiplex (Luminex/MSD)
Turnaround · availability
Send-out / research · Research-grade (no universal clinical assay)
Literature evidence(2)
- Novel Protein-Based Biomarkers of Out-of-hospital Sudden Cardiac Death After Myocardial Infarction.Circulation. Arrhythmia and electrophysiology · 2025 · PMID 40143805 · doi
- Identification of Adipsin as a Novel Prognostic Biomarker in Patients With Coronary Artery Disease.Journal of the American Heart Association · 2019 · PMID 31752640 · doi